InvestorsHub Logo
icon url

PickleNick

04/27/18 11:04 AM

#132044 RE: 2Relax #132025

This is such a great post.

It’s one thing when a consumer has to pay $50-$100 for medicine or something that eases pain.

It’s another when insurance companies pay for it, and the revenue it generates will be ridiculous.

icon url

Simpsonly

04/27/18 12:27 PM

#132097 RE: 2Relax #132025

Hey 2Relax - great post, thank you
"The way this marketing of the NHS is shaking out, this really is an unbelievable marketing concept. There will ALWAYS be ActiPatches in households as a result of this concept in the UK."

More on the marketing brilliance of the NHS decision to add ActiPatch to its insured Tariff . . . .

NHS can now actively market to Physicians AND Pharmacists in the UK . . . .Pharmacists can write a Script for ActiPatch for the patient right in the Pharmacy, by saying,

"Look, we cover drugs and now we cover ActiPatch. ActiPatch is drug-free, and safe and manages pain very well. In addition, it reduces edema (swelling, fluid) and stimulates healing at the molecular level. We have put it through trials in the UK and totally cleared it for OTC; the FDA in the U.S. has put it through trials and has OTC cleared it for foot and knee pain and is assessing the back and general pain now. Migraine and dysmenorrhea, severe menstrual cramping and pain will follow, and here's the two best parts, NHS will save hundreds of millions of pounds every year and our patients will be far better off using ActiPatch over drugs!" Helluva a pitch . . .

That is the NHS UK marketing pitch and it will be rolled out in the U.S. ASAP to Family Physicians and Surgeons, and Dentists, Pharmacists, Hospitals, Insurers, Medicare, Medicaid, The Blues . . . . . and most of all, to >140 odd million patients suffering from chronic pain and acute pain, plus those with migraines and dysmenorrhea, the overwhelming majority of whom are taking harmful drugs by the fistfull today. Over half the county! Billions of dollars on harmful drugs!

ActiPatch . . . Tsunami . . . . YKW . . . . .